{"code":1,"isDone":false,"toInsertArticleList":[{"createdTime":"2021-08-15 12:30:42","updatedTime":"2021-08-15 12:30:42","title":"德尔塔阴影下，mRNA疫苗能成为疫情解药吗？","link":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","description":"<div><div><div id=\"media\" class=\"rich_media_thumb_wrp\">\n\n            <img class=\"rich_media_thumb\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRNQmvWZ0NP6gibX1iaRTonfeTx5aHlyKfI1ZbxWcsQUwsiaciaU1trDPz21cUfHmRD0FgrzoAib8BJLa1w/0?wx_fmt=jpeg?imageView2/1/w/600\">\n        </div>\n    \n\n    \n\n    <div class=\"rich_media_content\" id=\"js_content\">\n                    \n\n                    \n                    \n                    \n                    <section style=\"text-align: center;padding: 0px 0.5em;margin-left: 8px;margin-right: 8px;\" data-mpa-powered-by=\"yiban.io\"><img class=\"rich_pages wxw-img js_insertlocalimg\" data-ratio=\"0.7725321888412017\" data-s=\"300,640\" data-type=\"png\" data-w=\"932\" style=\"box-shadow: rgb(210, 210, 210) 0em 0em 0.5em 0px; font-size: 17px; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRNQmvWZ0NP6gibX1iaRTonfeTZt36TgWq1loShdKp22T5YqeczMKDBrsiapJ9FVpflhTxONsLFVmN1tw/640?wx_fmt=png\"></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 12px;color: rgb(136, 136, 136);letter-spacing: 1px;\">Delta变异株的流行再次考验疫苗的有效性和接种率，mRNA疫苗能解燃眉之急吗？| 图源：pixabay.com</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></p><section data-tools=\"135编辑器\" data-id=\"97150\" data-width=\"95%\" style=\"margin-left: auto;margin-right: auto;width: 95%;flex: 0 0 95%;\"><section style=\"margin:10px auto;\"><section style=\"width: 55px;margin-right: auto;margin-left: auto;\"><img data-ratio=\"1\" data-type=\"png\" data-w=\"66\" data-width=\"100%\" style=\"box-sizing:border-box; width:100%; display:block; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/YUyZ7AOL3onWl7HutUicn4iaJ9r2icpgrK2Ut66gZ181iaGWFJaFibibCP2DT4e78Fe2qT8vT1Y5nUpTSupyvVYyiaOYg/640?wx_fmt=png\"></section><section style=\"margin-top: -30px;border-width: 3px;border-style: solid;border-color: rgb(110, 168, 248);padding: 2em 1em 1em;\"><section data-autoskip=\"1\" style=\"margin-top: 10px;font-size: 14px;letter-spacing: 1.5px;\"><section style=\"white-space: normal;margin-left: 8px;margin-right: 8px;line-height: 2em;margin-bottom: 10px;text-indent: 0em;text-align: center;\"><span style=\"letter-spacing: 1px;font-size: 16px;color: rgb(255, 255, 255);background-color: rgb(67, 120, 238);font-size: 16px;\"><strong> 导   读 </strong></span></section><p style=\"white-space: normal;text-indent: 2em;margin-left: 8px;margin-right: 8px;line-height: 2em;margin-bottom: 10px;\"><span style=\"letter-spacing: 1px;font-size: 14px;color: rgb(76, 69, 69);\">新冠病毒全球大流行以来，科学家们都在积极研发疫苗，数百上千个疫苗项目主要涉及8条技术路线，其中以核酸、病毒以及蛋白为基础的路线最受关注。</span></p><p style=\"white-space: normal;text-indent: 2em;margin-left: 8px;margin-right: 8px;line-height: 2em;margin-bottom: 10px;\"><span style=\"letter-spacing: 1px;font-size: 14px;color: rgb(76, 69, 69);\">从全球获批疫苗情况来看，主要包括三类：<strong>mRNA疫苗</strong>、<strong>灭活疫苗</strong>和<strong>腺病毒载体疫苗</strong>。灭活疫苗和腺病毒载体疫苗均已有产品在国内获批上市，而被普遍认为免疫原性更高的mRNA疫苗目前在欧美等发达国家广泛应用于接种，但尚未在中国大陆使用。</span></p><p style=\"white-space: normal;text-indent: 2em;margin-left: 8px;margin-right: 8px;line-height: 2em;margin-bottom: 10px;\"><span style=\"letter-spacing: 1px;font-size: 14px;color: rgb(76, 69, 69);\">最近，Delta变异株的流行再次考验疫苗的有效性和接种率，而国产mRNA疫苗研发进展以及国外mRNA疫苗何时引进，也成为公众关心的议题。</span></p></section><section style=\"display:flex;justify-content:flex-end;align-items: center;\"><section style=\"width: 10px;height: 10px;border-radius: 100%;background: rgb(140, 185, 249);overflow: hidden;\"><br></section><section style=\"width: 10px;height: 10px;border-radius: 100%;background: rgb(140, 185, 249);margin-right: 5px;margin-left: 5px;overflow: hidden;\"><br></section><section style=\"width: 10px;height: 10px;border-radius: 100%;background: rgb(140, 185, 249);overflow: hidden;\"><br></section></section></section></section></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><br></p><section style=\"margin-left: 16px;margin-right: 16px;line-height: 2em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><strong>撰文 | 王一苇</strong></span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: 2em;\"><strong><span style=\"font-size: 16px;letter-spacing: 1px;\">责编 | 刘楚</span></strong><span style=\"font-size: 16px;letter-spacing: 1px;\"></span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> <span style=\"font-size: 12px;letter-spacing: 1px;text-align: center;background-color: rgb(255, 255, 255);font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb>●               </span><span style=\"font-size: 12px;text-align: center;background-color: rgb(255, 255, 255);font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb>　</span><span style=\"font-size: 12px;letter-spacing: 1px;text-align: center;background-color: rgb(255, 255, 255);font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb>●               </span><span style=\"font-size: 12px;text-align: center;background-color: rgb(255, 255, 255);font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb>　</span><span style=\"font-size: 12px;letter-spacing: 1px;text-align: center;background-color: rgb(255, 255, 255);font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif rgb>●</span></span></p><section style=\"margin-left: 16px;margin-right: 16px;text-align: center;line-height: 2em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><br></span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">自7月20日以来，由南京禄口机场开始的新一轮新冠病毒疫情已传播至少15个省份，确诊六百多人。引起此次疫情传播的Delta变异株</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（B.1.617.2）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">导致了今年印度疫情暴发，并在全球快速传播，已成为美国、英国、日本等地的主要流行株，造成感染人数再度攀升，增加了各国政府的疫情防治压力。</span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[1-4]</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">疫情告急，疫苗的有效性问题牵动人心，关于接种第三针加强针以及开展不同种类疫苗、甚至有关研发针对Delta变异株的新疫苗也得到热烈讨论。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">此前有学者呼吁，<strong>国内应尽快提高疫苗的接种率，并引进有效性更高的mRNA疫苗，与灭活疫苗配合使用，以增强应对新冠病毒的效力。</strong></span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">那么，国产mRNA疫苗研究进展如何？mRNA疫苗作为灭活疫苗的第三针加强针是否可行？国人何时能用上mRNA疫苗？《知识分子》综合资料并对国内mRNA疫苗企业的负责人进行了访谈。</span></p><section style=\"margin-left: 16px;margin-right: 16px;line-height: 2em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></section><section data-tools=\"135编辑器\" data-id=\"97604\"><section style=\"text-align: center;margin:10px auto;\" hm_fix=\"201:215\"><section style=\"display: inline-block;width: 60px;\"><img data-ratio=\"1\" data-type=\"gif\" data-w=\"400\" data-width=\"100%\" style=\"box-sizing: border-box; width: 100%; max-width: 600px\" title=\"\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1uIDprqnrpyehGEx6GYBP7hiceHlanechCcbvbPyFkany2e2zIyxibRWg/640?wx_fmt=gif\"></section></section></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(56, 113, 219);\"><strong><span style=\"color: rgb(56, 113, 219);font-size: 16px;letter-spacing: 1px;\">突破感染案例频发，mRNA疫苗能有效对抗变异株吗？</span></strong></span></p><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><strong><span style=\"font-size: 16px;letter-spacing: 1px;\">原理上，mRNA疫苗在生产上的优势意味着它能更快应对变异株。</span></strong><span style=\"font-size: 16px;letter-spacing: 1px;\"></span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">mRNA疫苗的原理，是以新冠病毒主要引起免疫反应的S蛋白全长序列或S蛋白上受体结合区</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（RBD）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">序列为模版，合成一段mRNA序列，随后用一种特殊的脂质膜包裹，<strong>通过注射方式使mRNA进入人体上臂的肌肉细胞，在细胞质内生成蛋白，引起免疫反应。</strong></span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[5]</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">参与mRNA疫苗研发的华人科学家<strong>王年爽</strong>在接受《知识分子》采访时曾表示，mRNA制备简单，只要替换引发人体免疫反应的序列，就能比较快速应对一般常见的病毒S蛋白上的突变。目前的主要突变株，包括Delta，都是在S蛋白上发生了碱基对的替换。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">以目前的技术，出现疫苗突变株后，替换mRNA序列的速度较快。美国非盈利组织帕斯适宜卫生科技组织</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（PATH）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">疫苗创新和获取中心 Simone Blayer博士称 </span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[6]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">，即使使用现代发酵设备，达到足够的生物量以开始制造病毒性疫苗也需要大约四到六周的时间，每个生长和生产周期则可能需要一周时间，而<strong> “合成mRNA疫苗只需几分钟”。</strong></span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">具体到mRNA疫苗研发，“基本上4~6周就出一个新的疫苗，” 研发mRNA疫苗的斯微生物首席运营官张继国告诉《知识分子》。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><strong><span style=\"font-size: 16px;letter-spacing: 1px;\">但真实世界中，根据新毒株生产的新疫苗投入使用，仍需试验和审批时间。</span></strong><span style=\"font-size: 16px;letter-spacing: 1px;\">美国辉瑞和德国BioNTech虽然宣布已经根据Delta毒株研发了新疫苗，且将在今年8月进入临床试验，但其真正投入使用的时间仍然未知 </span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[7]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><strong><span style=\"font-size: 16px;letter-spacing: 1px;\">目前，市面上已经接种的mRNA疫苗，大多仍是根据早期毒株序列制造的。</span></strong><span style=\"font-size: 16px;letter-spacing: 1px;\">多项研究显示，mRNA疫苗针对变异株的保护率未有大幅降低。</span><span style=\"font-size: 16px;letter-spacing: 1px;\"></span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">2021年3月，辉瑞/BioNtech的mRNA疫苗在英格兰的研究数据显示，两针后疫苗对Delta变异株出现感染症状的保护率约为88%。6月，苏格兰公共卫生部门等发布的研究显示辉瑞/BioNTech的疫苗针对Delta变异株的保护率约为79%。7月初，加拿大研究则显示对Delta保护率为87%，与Alpha及其他变异株的保护率相当。</span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[8-10]</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">颇令人担忧的数据来自以色列。5月以色列政府数据显示，辉瑞/BioNTech防感染的保护率仅为64%；7月以色列的最新数据显示，辉瑞/BioNTech的疫苗防感染的保护率降至39%。<strong>这也意味着mRNA疫苗有可能无法有效阻止病毒扩散。</strong></span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[11-12]</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">不过，以色列尚未公布这些结果背后的详细数据。当地一些专家认为，目前的统计结果可能因为种种原因并不准确，包括感染人数仍然过少、未接种人群感染率不准等 </span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[13]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">此外，另一个曾被寄望供应发展中国家的mRNA疫苗，对变异株的保护率也不容乐观。6月，德国疫苗公司CureVac公布数据，其新冠mRNA疫苗三期临床试验保护率仅为47%。CureVac使用的mRNA序列未经修饰，而BioNTech和Moderna都做了碱基修饰。CureVac声称，保护率低是因为其三期临床面对的毒株是多种变异株 </span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[14]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">虽然总体保护率不低，<strong>mRNA疫苗突破案例，即接种过疫苗后仍然感染的病例，仍频频发生。</strong>7月上旬，美国马萨诸塞州一个小镇，在举行大型活动后新增了469个新冠感染病例，美国疾控中心</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（CDC）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">研究感染者的数据后发现，其中74%的人接种过辉瑞、Moderna或强生的疫苗 </span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[15]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">Delta变异株的高传播力，迫使美国CDC重新建议民众戴上口罩。不过，美国CDC也称，<strong>疫苗突破案例是 “预料之中的”——即使打了疫苗，仍有一小部分人可能感染、入院甚至死亡</strong> </span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[16-17]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><section data-tools=\"135编辑器\" data-id=\"97604\"><section style=\"text-align: center;margin:10px auto;\" hm_fix=\"217:230\"><section style=\"display: inline-block;width: 60px;\"><img data-ratio=\"1\" data-type=\"gif\" data-w=\"400\" data-width=\"100%\" style=\"box-sizing: border-box; width: 100%; max-width: 600px\" title=\"\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1u9ib5iawOKyrel83Tog3RBiaJhGJmgxHSsx3mGibpLtdyiahmv407vQuKcw/640?wx_fmt=gif\"></section></section></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(56, 113, 219);\"><strong><span style=\"color: rgb(56, 113, 219);font-size: 16px;letter-spacing: 1px;\">国产mRNA疫苗研发正在跟进变异株</span></strong></span></p><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">《知识分子》了解到，<strong>中国本土研发的mRNA疫苗，仍以针对早期毒株为主，但也正在跟进变异株的疫苗研究。</strong></span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">正在研发mRNA疫苗的公司斯微生物首席运营官<strong>张继国</strong>告诉《知识分子》，<strong>目前斯微生物研制的mRNA疫苗有两种，一种以中国疾控中心高福团队最早发布的病毒序列为基础，一种以南非变异株的序列为基础。</strong>即将开始的国内二期临床试验中，两种疫苗都会纳入。而海外即将展开的临床试验将针对新冠病毒的变异株为主。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">不过，关于国内mRNA疫苗有效性的数据仍是空缺。截至8月5日，中国本土的mRNA疫苗公司仅有艾博生物一家进入三期临床试验，尚未公布三期试验结果。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">艾博生物CEO<strong>英博</strong>在今年4月接受《知识分子》采访时称，其mRNA疫苗ARCoV一期临床试验 “结果很不错，跟国外的</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（mRNA疫苗）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">基本上是可比的”，二期结果 “还不便透露”；三期临床将展开国际多中心研究，以南美洲国家为主。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">ARCoV是基于早期毒株的疫苗。2020年9月，艾博生物在《细胞</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（<em>Cell</em>）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">》杂志上发表动物实验结果，显示ARCoV在小鼠和食蟹猴模型中能产生高滴度的抗体并防止新冠病毒感染 </span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[18]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。英博在今年6月对《第一财经》表示</span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\"> [19]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">，今年会推动针对贝塔、德尔塔这两个变异株的mRNA疫苗进入临床。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">不过，该疫苗人体临床试验的具体结果尚未公布，也没有相关的论文发表。</span></p><section style=\"margin-left: 16px;margin-right: 16px;line-height: 2em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></section><section data-tools=\"135编辑器\" data-id=\"97604\"><section style=\"text-align: center;margin:10px auto;\"><section style=\"display: inline-block;width: 60px;\"><img data-ratio=\"1\" data-type=\"gif\" data-w=\"400\" data-width=\"100%\" style=\"box-sizing: border-box; width: 100%; max-width: 600px\" title=\"\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1eSIujfuJjFDyYUbjQUAaNy1icFEHnOV97drE2R6EAxshPtoz8aPLLSg/640?wx_fmt=gif\"></section></section></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(56, 113, 219);\"><strong><span style=\"color: rgb(56, 113, 219);font-size: 16px;letter-spacing: 1px;\">mRNA疫苗作为加强针和混打，效果如何？</span></strong></span></p><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">Delta突变株的高传播力和突破性感染，使得国外一些政府开始认真考虑给完成两针疫苗接种的人群补打加强针。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">在美国，辉瑞和Moderna认为前两针疫苗的效用会随时间减弱，正在推动批准加强针。但7月初，美国CDC和美国药品监督管理局</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（FDA）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">发表联合声明，认为目前还未看到加强针的必要性。不过，<strong>在德尔塔疫情影响下，一些民众已经开始自发接种第三针</strong>，而美国CDC也表示正在追踪数据。</span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[20-22]</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">国内南京疫情暴发以后，关于接种第三针的讨论也逐渐多了起来。人们希望知道，2020年底国家药监局批准第一个国产灭活新冠疫苗，距今已半年有余，最早一批疫苗接种者是否需要接种加强针？</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">江苏省疾病预防控制中心疫苗评价所联合复旦大学公共卫生学院、科兴生物等多家机构，研究了接种两针科兴疫苗后28天至8个月，再接种第三针的效果。结果显示，接种第三剂后中和抗体滴度显著提高，第三剂28天中和抗体滴度比第二剂28天中和抗体滴度增加了3-5倍，且第三剂与第二剂间隔时间越长，增长倍数越高。相关论文7月25日发表于预印本平台Medrxiv，尚未经同行评议。</span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[23]</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><strong><span style=\"font-size: 16px;letter-spacing: 1px;\">不同技术路线的疫苗混打试验也在进行中。</span></strong><span style=\"font-size: 16px;letter-spacing: 1px;\"></span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">7月初，江苏疾控中心副主任<strong>朱凤才</strong>在一场行业会议上中透露，疫苗的 “序贯” 试验已在进行。与两个不同生产商的灭活疫苗的 “混打” 不同，“序贯” 指的是按顺序接种不同技术路线的疫苗。他解释说，之所以进行这样的试验，是因为全球来看，新冠疫苗中 <strong>“安全性好的效果欠佳，效果好的安全性没有那么</strong></span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（好）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">”。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">朱凤才透露，目前已完成的试验显示，两针灭活疫苗基础上序贯一针阿斯利康腺病毒载体疫苗，其免疫反应优于加强免疫一针灭活疫苗；而一针灭活疫苗基础上序贯一针载体疫苗，反应优于两针灭活疫苗。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">5月，斯微生物提交在医学研究预发表网站MedRxiv上的一篇论文，描述了一对夫妇在接种新冠灭活疫苗7个月后，再次接种斯微的mRNA疫苗的情况，显示其特异性抗体和记忆B细胞、记忆T细胞均有 “显著提升”，且没有显著不良反应。该论文尚未通过同行评议。</span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[24]</span></p><section style=\"margin-left: 16px;margin-right: 16px;line-height: 2em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></section><section data-tools=\"135编辑器\" data-id=\"97604\"><section style=\"text-align: center;margin:10px auto;\"><section style=\"display: inline-block;width: 60px;\"><img data-ratio=\"1\" data-type=\"gif\" data-w=\"400\" data-width=\"100%\" style=\"box-sizing: border-box; width: 100%; max-width: 600px\" title=\"\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1IzHStGwKibmYIkGvImBZxibKX0LejQIWFC9cwGx1dicfNoLVbSK7f0LkQ/640?wx_fmt=gif\"></section></section></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(56, 113, 219);\"><strong><span style=\"color: rgb(56, 113, 219);font-size: 16px;letter-spacing: 1px;\">mRNA疫苗副作用真的很大吗？</span></strong></span></p><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">目前已经广泛使用的两种mRNA疫苗，以极高的效力著称，但相比灭活疫苗，观察到的副作用也更多。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">辉瑞/BioNTech和Moderna的三期临床结果均显示，mRNA疫苗呈现轻度到中度的副作用，包括虚弱、头痛、肌肉酸痛、腹泻和寒战等。但发生严重不良反应的接种者是少数，据《科学》杂志，辉瑞和Moderna疫苗接种后发高烧的人群比例不到2%。</span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[25-26]</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">Moderna的一期临床结果显示，<strong>副作用与剂量呈现正相关。</strong>一剂250微克的疫苗导致副作用的比例高于100微克，但免疫效果并没有显著提升。目前，Moderna采用的是100微克每剂，辉瑞/BioNtech采用的是30微克每剂。</span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[27-29]</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">据《自然》杂志报道，德国制药公司CureVac的mRNA疫苗在一期临床采用20微剂量接种时，副作用明显，出现了严重头痛、虚弱、寒战等；而12微克的剂量接种时尽管副作用在可接受的范围，但有效性明显低于另外两款mRNA疫苗。</span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[30]</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">不过，这些副作用都是短期的，据美国CDC官网，副作用可能影响人的日常活动，但“几天后副作用就会消失”</span><span style=\"letter-spacing: 1px;font-size: 14px;color: rgb(136, 136, 136);\">[31]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"><br></span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">据《知识分子》了解，<strong>mRNA疫苗对亚洲人群的副作用是目前在研试验项目关注的重点之一。</strong></span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">在上述行业会议中，朱凤才表示，mRNA疫苗的免疫原性较好，但国内临床试验接种后，尤其是第二针之后的不良反应较大，“mRNA疫苗虽然好，你打了之后会有感受，副作用比较大，大面积接种过程中，青壮年有心肌炎、过敏。”</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">朱凤才介绍，腺病毒载体疫苗的常见不良反应也较大，包括发热和疲劳等。相对而言，灭活疫苗和铝佐剂蛋白疫苗的不良反应发生率最低，但效力相对较弱。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">“我做过8个疫苗</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（的临床试验）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">特别有体会，像mRNA和载体疫苗做临床的时候，一些患者上午接种，晚上基本四点钟才会睡觉，发热8个小时到14个小时……要及时处理。这一块非常明显。第一针有发热反应的，第二针一定有发热反应，并且第二针发热反应明显高得多，” 朱凤才说。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"></span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">张继国也透露，临床试验中发现，中国人体质上对mRNA疫苗的耐受性与欧美有差异，因而他们的mRNA疫苗一期临床花费时间相对较长，“国家局对mRNA</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（疫苗的审评审批）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">还是比较谨慎，每组都有哨兵的时间，整个战线都拉得非常长”。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">张继国说，斯微设置的剂量组从25微克到100微克不等。但在临床试验过程中发现，剂量越大，副作用就越大。“正式</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（临床试验）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">还没有完成，我们就把100微克停掉了。” 他说，由于观察到的副作用较大，最终的剂量可能在50微克以下。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">尽管如此，张继国认为副作用仍然是 “好预测” 的。“我觉得它</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（mRNA疫苗）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">的副作用</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（人体）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">是就可以承受的，”他以自己接种时的反应举例说明，“当时我是有发烧的，凌晨烧，白天就好了，我觉得倒没什么特别的。”</span></p><section data-tools=\"135编辑器\" data-id=\"97604\"><section style=\"text-align: center;margin:10px auto;\"><section style=\"display: inline-block;width: 60px;\"><img data-ratio=\"1\" data-type=\"gif\" data-w=\"400\" data-width=\"100%\" style=\"box-sizing: border-box; width: 100%; max-width: 600px\" title=\"\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1xRUaEePib7nPUBgOaQJfrGIYTA77ZsGpbEyd7PbYNpAkM5IVQf0t5mg/640?wx_fmt=gif\"></section></section></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(56, 113, 219);\"><strong><span style=\"color: rgb(56, 113, 219);font-size: 16px;letter-spacing: 1px;\">国内何时能打上mRNA疫苗？</span></strong></span></p><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><strong><span style=\"font-size: 16px;letter-spacing: 1px;\">中国新冠mRNA疫苗启动时间与国外几家公司同步甚至更早，但研发进度相对缓慢。</span></strong><span style=\"font-size: 16px;letter-spacing: 1px;\">目前仅有一家公司的产品进入三期临床。除了领跑的艾博生物和斯微生物，丽凡达生物，蓝鹊生物等几家公司也已入局。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">艾博生物已在国内外分别开展临床三期试验。5月30日，艾博生物mRNA疫苗ARCoV的三期临床在墨西哥启动，这也是中国第一个进入临床三期的mRNA疫苗，预计入组6000人 </span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[32]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。7月21日，艾博生物的合作方沃森生物申请注册了mRNA疫苗在国内的三期临床试验，预计入组2000人，试验将在广西的三个疾病预防控制中心展开 </span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[33]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">英博在接受《知识分子》采访时表示，艾博生物自2020年1月就开始和军事科学院下属的军事医学研究院合作研制疫苗。疫苗样品在苏州制备，通过高铁送往北京开展临床前的动物实验。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">据中国临床试验注册中心公开信息，ARCoV的一期临床试验在树兰</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（杭州）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">医院和广西壮族自治区永福县疾病预防控制中心展开，入组168人，测试了低中高三个剂量疫苗的接种效果。此外，一期b临床试验同样在树兰医院经过伦理审批，入组120人，测试了5-25微克</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（µg）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">间5个不同剂量疫苗的接种效果。今年1月由合作伙伴云南沃森生物申请注册的二期临床试验，则测试了5、10、15微克的接种效果。</span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[34-36]</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">进度仅次于艾博生物的是斯微生物。张继国告诉《知识分子》，斯微生物的mRNA疫苗即将在河南开始二期临床试验，并已在老挝拿到了临床试验的批件，接下来还计划在孟加拉国、吉尔吉斯斯坦和斯里兰卡等国申请临床批件，“最理想的情况可能是9月底在这些国家拿到批复。”</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">斯微生物的一期临床试验相对较晚，今年3月25日才正式启动。张继国解释，这是因为他们的技术路线不同，有关部门要求临床前做更多的动物实验验证。据中国临床试验注册中心登记信息，斯微生物一期临床试验与树兰</span><span style=\"font-size: 16px;letter-spacing: 1px;color: rgb(136, 136, 136);\">（杭州）</span><span style=\"font-size: 16px;letter-spacing: 1px;\">医院合作完成 </span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[37]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">张继国透露，<strong>除了由药企申请的临床试验外，目前国内也有一些研究机构用斯微生物提供的mRNA疫苗发起临床研究</strong>，这类不以上市为目的的临床试验经研究单位伦理委员会审批通过即可。发起的机构包括上海东方医院和中国医学科学院医学生物学研究所等<span style=\"font-size: 16px;letter-spacing: 1px;\"> </span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[38]</span>，参与试验的接种者达200多人</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">普通民众什么时候能打上国产mRNA疫苗？张继国预计，“年底可能会有大规模的供应。”</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><strong><span style=\"font-size: 16px;letter-spacing: 1px;\">除了国产mRNA疫苗的研发进展，何时引进国外已获批的mRNA疫苗也是公众关注的焦点。</span></strong><span style=\"font-size: 16px;letter-spacing: 1px;\"></span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">目前，mRNA疫苗公司辉瑞/BioNTech和Moderna的疫苗尚未供应中国大陆。复星医药作为辉瑞mRNA疫苗在大中华区唯一合作方，已将疫苗引进香港和台湾地区。根据财新7月15日的报道，复星医药在股东大会上透露，辉瑞/BioNTech疫苗已通过国家药监局的专家审评，进入了行政审批阶段</span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\"> [39]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。</span></p><section style=\"margin-left: 16px;margin-right: 16px;line-height: 2em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></section><section data-tools=\"135编辑器\" data-id=\"97604\"><section style=\"text-align: center;margin:10px auto;\" hm_fix=\"412:198\"><section style=\"display: inline-block;width: 60px;\"><img data-ratio=\"1\" data-type=\"gif\" data-w=\"400\" data-width=\"100%\" style=\"box-sizing: border-box; width: 100%; max-width: 600px\" title=\"\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1ricSyknndpMBaK5Tjk2vcx0of3l4oKCyWFyEF0Yq5t974WPFicRCYSXw/640?wx_fmt=gif\"></section></section></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;text-align: center;\"><span style=\"color: rgb(56, 113, 219);\"><strong><span style=\"color: rgb(56, 113, 219);font-size: 16px;letter-spacing: 1px;\">国内mRNA疫苗产能如何？</span></strong></span></p><section style=\"margin-left: 16px;margin-right: 16px;line-height: 1.5em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">无论是自主研发还是引进，mRNA疫苗的产能，是影响其在疫情防控中发挥多大作用的重要因素。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">复星医药和BioNTech除了签订协议进口疫苗，还成立了合资公司，以推动本地化生产。据经济观察网报道，复星医药在上海的合作厂房当前年产能为3.5到4.2亿剂，同时正在计划扩充到10亿剂 </span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[40-41]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">而斯微生物的张继国表示，目前从国内的原料供应来看，即使协调所有供应商，<strong>让10亿人每人都打两针 “很难”，但可以给重点人群打补充针</strong>，“如果明年有几亿针，也能解决很多问题。”</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">斯微生物尚未公布产能数据。2020年9月，其合作方西藏药业曾公告在上海临港购买房屋土地，进行生产线建设</span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\"> [42]</span><span style=\"font-size: 16px;letter-spacing: 1px;\">。</span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"font-size: 16px;letter-spacing: 1px;\">艾博生物的合作方沃森生物，在云南建设的mRNA新冠病毒疫苗生产车间预计一期产能为1.2亿剂/年。此外，艾博生物在苏州的首个符合GMP标准的mRNA疫苗生产基地已建成，预计年产能将达到4000万人份单剂。</span><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[43-44] <strong style=\"font-family: -apple-system, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif normal rgb><span style=\"color: rgb(47, 113, 200);\"><strong style=\"letter-spacing: 0.544px;color: rgb(136, 136, 136);\"><span style=\"color: rgb(202, 48, 25);\"><img class=\"rich_pages\" data-ratio=\"0.9782608695652174\" data-s=\"300,640\" data-type=\"png\" data-w=\"92\" style=\"font-family: -apple-system-font, BlinkMacSystemFont,; max-width: 600px\" helvetica neue sc sans gb yahei ui arial sans-serif rgb border-box visible src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRM5Ud8d7rOrOJZmevzXI7jkWPQBKNS1T4U2CFbBsLHLZqKukUV52RiaDRiaVKuLnOshZeeEDWuDse3w/640?wx_fmt=png\"></span></strong></span></strong></span></p><section style=\"margin-left: 16px;margin-right: 16px;line-height: normal;\"><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\"><strong style=\"font-family: -apple-system, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif normal rgb><span style=\"color: rgb(47, 113, 200);\"><strong style=\"letter-spacing: 0.544px;color: rgb(136, 136, 136);\"><span style=\"color: rgb(202, 48, 25);\"><br></span></strong></span></strong></span></section><section style=\"margin-left: 16px;margin-right: 16px;line-height: normal;\"><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\"><span style=\"color: rgb(47, 113, 200);\"><span style=\"color: rgb(202, 48, 25);\"><span style=\"color: rgb(136, 136, 136);font-size: 14px;letter-spacing: 1px;\">（叶水送、宁辉对本文亦有贡献）</span></span></span></span></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: 1.75em;\"><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\"><strong style=\"font-family: -apple-system, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif normal rgb><span style=\"color: rgb(47, 113, 200);\"><strong style=\"letter-spacing: 0.544px;color: rgb(136, 136, 136);\"><span style=\"color: rgb(202, 48, 25);\"><br></span></strong></span></strong></span></p><section style=\"text-align: center;padding: 0px 0.5em;margin-left: 8px;margin-right: 8px;\"><img class=\"rich_pages wxw-img\" data-galleryid=\"\" data-ratio=\"0.4236842105263158\" data-s=\"300,640\" data-type=\"jpeg\" data-w=\"760\" style=\"box-shadow: rgb(210, 210, 210) 0em 0em 0.5em 0px; font-size: 17px; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRO3Sj5JqOfIxBuplfCx6EdiaHeBopib80SfvU0pKAvPD1rjefmLAcX9sIJGkqgTxK0GsNWjlufSuzKg/640?wx_fmt=jpeg\"></section><p style=\"margin-left: 16px;margin-right: 16px;line-height: normal;\"><span style=\"font-size: 16px;letter-spacing: 1px;\"> </span></p><section powered-by=\"xiumi.us\" style=\"font-family: -apple-system, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif normal rgb><section data-role=\"paragraph\" style=\"letter-spacing: 0.544px;font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif><section data-role=\"paragraph\" style=\"letter-spacing: 0.544px;font-family: -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;\"><section style=\"letter-spacing: 0.544px;\"><section style=\"margin-right: 8px;margin-left: 8px;text-align: left;width: 677px;line-height: 1.5em;\"><section style=\"display: inline-block;width: 677px;height: 240px;vertical-align: top;overflow-y: auto;\"><section style=\"overflow-x: hidden;\"><section powered-by=\"135编辑器\" style=\"margin-top: 20px;\"><section style=\"padding: 0.1em 0.3em;display: inline-block;border-width: 2px;border-style: solid;border-color: rgb(252, 251, 251);\"><section data-role=\"outer\"><section data-role=\"paragraph\"><p style=\"margin-right: 16px;margin-left: 16px;color: rgb(62, 62, 62);font-size: 16px;letter-spacing: 1px;line-height: 1.5em;\"><strong style=\"color: rgb(123, 127, 131);font-size: 14px;\"><strong style=\"font-family: -apple-system, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif><span style=\"color: rgb(47, 113, 200);\"><strong style=\"letter-spacing: 0.544px;color: rgb(136, 136, 136);\"><span style=\"color: rgb(202, 48, 25);\"><strong style=\"letter-spacing: 1px;\"><span style=\"color: rgb(136, 136, 136);font-size: 14px;\"><img class=\"__bg_gif\" data-ratio=\"1\" data-type=\"gif\" data-w=\"200\" style=\"font-family: -apple-system-font, BlinkMacSystemFont,; max-width: 600px\" helvetica neue sc sans gb yahei ui arial sans-serif border-box visible src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/LHibUTtMHPRM5Ud8d7rOrOJZmevzXI7jkbtS6NgcCtYfhOYnbRDqWPyibaelA4pIB0lvdg99hJfsmdibm2Eibg6dDQ/640?wx_fmt=gif\"> </span></strong></span></strong></span></strong>参考资料</strong><span style=\"color: rgb(136, 136, 136);font-size: 14px;\">（上下滑动可浏览）</span><span style=\"color: rgb(136, 136, 136);font-size: 14px;\"></span></p><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">[1]https://mp.weixin.qq.com/s/_-LpdpRYCFh24W5-T4gRKQ</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[2]https://m.thepaper.cn/newsDetail_forward_13899350</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[3]https://www.bbc.com/news/world-asia-india-55472333</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[4]https://www.yalemedicine.org/news/5-things-to-know-delta-variant-covid</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[5]https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[6]https://www.path.org/articles/mrna-and-future-vaccine-manufacturing/</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[7]https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-ask-fda-authorize-booster-dose-covid-vaccine-delta-variant-spreads-2021-07-08/</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[8] https://www.medrxiv.org/content/10.1101/2021.05.22.21257658v1</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[9] https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01358-1/fulltext</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[10] https://www.medrxiv.org/content/10.1101/2021.06.28.21259420v1</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[11]https://www.gov.il/en/departments/news/05072021-03</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[12]https://www.cnbc.com/2021/07/23/delta-variant-pfizer-covid-vaccine-39percent-effective-in-israel-prevents-severe-illness.html</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[13]https://www.timesofisrael.com/israeli-uk-data-offer-mixed-signals-on-vaccines-potency-against-delta-strain/</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[14]https://www.nature.com/articles/d41586-021-01661-0</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"letter-spacing: 1px;color: rgb(136, 136, 136);font-size: 14px;\">https://www.ft.com/content/ad5191e6-870e-4c45-9d22-9d989d53511f</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[15]https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[16]https://www.cnbc.com/2021/07/30/cdc-study-shows-74percent-of-people-infected-in-massachusetts-covid-outbreak-were-fully-vaccinated.html</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[17]https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[18]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377714/</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[19]https://www.yicai.com/news/101082982.html</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[20]https://edition.cnn.com/2021/07/08/health/pfizer-waning-immunity-bn/index.html</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[21]https://www.hhs.gov/about/news/2021/07/08/joint-cdc-and-fda-statement-vaccine-boosters.html#:~:text=Americans%20who%20have%20been%20fully,a%20booster%20might%20be%20necessary.</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[22]https://thehill.com/changing-america/well-being/prevention-cures/566083-some-americans-sneaking-third-vaccine-shots-as</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[23]https://www.medrxiv.org/content/10.1101/2021.07.23.21261026v1</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[24]https://www.medrxiv.org/content/10.1101/2021.05.17.21257134v1</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[25]https://www.fiercepharma.com/vaccines/pfizer-sees-mostly-mild-to-moderate-safety-profile-phase-3-covid-vaccine-study</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[26]https://www.sciencemag.org/news/2020/11/fever-aches-pfizer-moderna-jabs-aren-t-dangerous-may-be-intense-some</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[27]https://www.nejm.org/doi/full/10.1056/NEJMoa2022483</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[28]https://www.reuters.com/business/healthcare-pharmaceuticals/lonza-add-dutch-production-line-boost-moderna-covid-19-vaccine-2021-06-02/</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[29]https://www.forbes.com/sites/brucelee/2020/12/19/pfizer-biontech-and-moderna-covid-19-vaccines-here-are-5-differences/?sh=7404224932cf</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[30]https://www.nature.com/articles/d41586-021-01661-0</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[31]https://chinese.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[32]https://www.reuters.com/article/health-coronavirus-mexico-walvax-idCNL1N2MZ00Z</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[33]https://www.chictr.org.cn/showproj.aspx?proj=130672</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[34]http://www.chictr.org.cn/showproj.aspx?proj=55524</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[35]http://www.chictr.org.cn/showproj.aspx?proj=63183</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[36]http://www.chictr.org.cn/showproj.aspx?proj=119719</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[37]http://www.chictr.org.cn/showproj.aspx?proj=126046</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[38]http://www.chictr.org.cn/showproj.aspx?proj=128920</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[39]https://www.caixin.com/2021-07-14/101740353.html</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[40]https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0509/2021050900125_c.pdf</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[41]http://www.eeo.com.cn/2021/0513/487937.shtml</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[42]http://data.eastmoney.com/notices/detail/600211/AN202009071408858190.html</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[43]http://www.walvax.com/Info/1/1192/index.aspx</span></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;text-align: left;line-height: 1.5em;\"><span style=\"color: rgb(136, 136, 136);letter-spacing: 1px;font-size: 14px;\">[44]http://www.sipac.gov.cn/kjzszx/xwzx/202107/fc034bcd612b4af29493623860726c1b.shtml</span></section></section></section></section></section></section></section></section></section></section></section></section><section powered-by=\"135编辑器\" style=\"letter-spacing: 0.544px;white-space: normal;background-color: rgb(255, 255, 255);font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif><p style=\"margin-right: 16px;margin-left: 16px;text-align: right;letter-spacing: 1px;line-height: normal;\"><br></p></section><section powered-by=\"135编辑器\" style=\"letter-spacing: 0.544px;white-space: normal;background-color: rgb(255, 255, 255);font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif><p style=\"margin-right: 16px;margin-left: 16px;text-align: right;letter-spacing: 1px;line-height: normal;\"><span style=\"font-size: 14px;color: rgb(136, 136, 136);letter-spacing: 0.54px;font-family: -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;\">制版编辑 </span><span style=\"font-size: 14px;color: rgb(255, 76, 0);letter-spacing: 0.54px;font-family: -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;\">| </span><span style=\"font-size: 14px;color: rgb(136, 136, 136);letter-spacing: 0.54px;font-family: -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;\">卢卡斯</span></p></section><section label=\"Powered by 135editor.com\" data-role=\"outer\" style=\"white-space: normal;background-color: rgb(255, 255, 255);font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif><section data-role=\"paragraph\"><section data-role=\"paragraph\"><section data-id=\"95447\" data-width=\"96%\" data-tools=\"135编辑器\" style=\"margin-right: auto;margin-left: auto;width: 649.9px;\"><section data-width=\"100%\" style=\"margin: 1em auto;width: 649.9px;\"><section data-autoskip=\"1\" style=\"margin-top: -10px;padding: 1em;border-width: 1px;border-style: solid;border-color: rgb(255, 255, 255);color: rgb(255, 255, 255);line-height: 1.75em;letter-spacing: 1.5px;font-size: 14px;\"><section style=\"margin-right: 16px;margin-left: 16px;\"><br></section><section data-role=\"paragraph\"><section style=\"margin-right: 16px;margin-left: 16px;text-align: center;\"><img border=\"0\" class=\"__bg_gif\" data-ratio=\"0.08658008658008658\" data-type=\"gif\" data-w=\"462\" data-width=\"80%\" height=\"\" style=\"letter-spacing: 0.54px; box-sizing: border-box !important; visibility: visible !important; width: 470.31px !important; max-width: 600px\" title=\"\" width=\"80%\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/lBLXrFcccXFwZwrMI7x3Idm0WicwB4ibviaNqA7dU3PEVQZrafvvMVQV4muo1DuHlPLtLIAwFbMWic5VGyn7G1vIuQ/640?wx_fmt=gif\"></section></section></section></section></section></section></section></section><p style=\"margin-right: 16px;margin-bottom: 5px;margin-left: 16px;white-space: normal;background-color: rgb(255, 255, 255);font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif center><a target=\"_blank\" href=\"http://mp.weixin.qq.com/s?__biz=MzIyNDA2NTI4Mg==&amp;mid=2655478925&amp;idx=1&amp;sn=fdc2a5a7298565c1f6af1c0b84a16363&amp;chksm=f3a766e0c4d0eff60dad2d49803c06fb1cdf713b4603dc523493cb02bf80c4581e8443764d7a&amp;scene=21#wechat_redirect\" textvalue=\"你已选中了添加链接的内容\" data-itemshowtype=\"0\" tab=\"innerlink\" data-linktype=\"1\"><span class=\"js_jump_icon h5_image_link\" data-positionback=\"static\" style=\"top: auto;left: auto;margin: 0px;right: auto;bottom: auto;\"><img class=\"rich_pages\" data-cropselx1=\"0\" data-cropselx2=\"520\" data-cropsely1=\"0\" data-cropsely2=\"131\" data-ratio=\"0.2520833333333333\" data-s=\"300,640\" data-type=\"jpeg\" data-w=\"960\" style=\"border-width: 0px; border-style: initial; border-color: initial; border-radius: 12px; top: auto; left: auto; right: auto; bottom: auto; box-sizing: border-box !important; visibility: visible !important; width: 520px; height: 131px; margin: 0px; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRNQmvWZ0NP6gibX1iaRTonfeT0elRibzgOSXQjFbVlxwdIaibHBkFMATRmXn52h3jHo1PWf2IcVu7UOAQ/640?wx_fmt=jpeg\"></span></a></p><section style=\"margin-right: 16px;margin-bottom: 10px;margin-left: 16px;white-space: normal;background-color: rgb(255, 255, 255);font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif center><a target=\"_blank\" href=\"http://mp.weixin.qq.com/s?__biz=MzIyNDA2NTI4Mg==&amp;mid=2655473963&amp;idx=1&amp;sn=9af4f1c1a391d4030211d734ec34c807&amp;chksm=f3a75346c4d0da50ab7406910419f47b53d4b1aa6e3cc4fa9f61706b9e4c8de6744d3abd87ad&amp;scene=21#wechat_redirect\" textvalue=\"你已选中了添加链接的内容\" data-itemshowtype=\"0\" tab=\"innerlink\" data-linktype=\"1\" hasload=\"1\" style=\"-webkit-tap-highlight-color: rgba(0, 0, 0, 0);cursor: pointer;letter-spacing: 0.54px;\"><span class=\"js_jump_icon h5_image_link\" data-positionback=\"static\" style=\"line-height: 0;vertical-align: bottom;top: auto;left: auto;right: auto;bottom: auto;\"><img class=\"rich_pages\" data-cropselx1=\"0\" data-cropselx2=\"520\" data-cropsely1=\"0\" data-cropsely2=\"131\" data-ratio=\"0.2520833333333333\" data-s=\"300,640\" data-type=\"jpeg\" data-w=\"960\" style=\"border-width: 0px; border-style: initial; border-color: initial; letter-spacing: 0.54px; border-radius: 12px; top: auto; left: auto; right: auto; bottom: auto; box-sizing: border-box !important; visibility: visible !important; width: 520px !important; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRMe9wA4tOj4PflDJ7GITMsXqzKllK1PTSglkLTkVVZHsHlVkPReUw9eCqdXHjDOQOArP0xDZibn3Xg/640?wx_fmt=jpeg\"></span></a><br></section><section style=\"margin-right: 16px;margin-left: 16px;white-space: normal;background-color: rgb(255, 255, 255);font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif center normal><a target=\"_blank\" href=\"http://mp.weixin.qq.com/s?__biz=MzIyNDA2NTI4Mg==&amp;mid=2655473963&amp;idx=1&amp;sn=9af4f1c1a391d4030211d734ec34c807&amp;chksm=f3a75346c4d0da50ab7406910419f47b53d4b1aa6e3cc4fa9f61706b9e4c8de6744d3abd87ad&amp;scene=21#wechat_redirect\" textvalue=\"你已选中了添加链接的内容\" data-itemshowtype=\"0\" tab=\"innerlink\" data-linktype=\"1\" hasload=\"1\" style=\"-webkit-tap-highlight-color: rgba(0, 0, 0, 0);cursor: pointer;letter-spacing: 0.54px;\"><span class=\"js_jump_icon h5_image_link\" data-positionback=\"static\" style=\"line-height: 0;vertical-align: bottom;top: auto;left: auto;right: auto;bottom: auto;\"><img class=\"rich_pages\" data-cropselx1=\"0\" data-cropselx2=\"520\" data-cropsely1=\"0\" data-cropsely2=\"131\" data-ratio=\"0.2520833333333333\" data-s=\"300,640\" data-type=\"jpeg\" data-w=\"960\" style=\"border-width: 0px; border-style: initial; border-color: initial; border-radius: 12px; top: auto; left: auto; right: auto; bottom: auto; box-sizing: border-box !important; visibility: visible !important; width: 520px !important; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRP0zxsk2TMjOnBEVlg7iciaJY93KSTmibPiaQMWK0mRuiagdEpUuI2NASRiciaJSmI7xOsYcNU2CQtDL6B8A/640?wx_fmt=jpeg\"></span></a></section><p style=\"margin-right: 16px;margin-left: 16px;white-space: normal;background-color: rgb(255, 255, 255);font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif right><br></p><section data-role=\"paragraph\" style=\"white-space: normal;background-color: rgb(255, 255, 255);font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif><section label=\"Powered by 135editor.com\" data-role=\"outer\"><section data-role=\"paragraph\"><section label=\"Powered by 135editor.com\" data-role=\"outer\"><section label=\"Powered by 135editor.com\" data-role=\"outer\"><section data-id=\"95265\" data-tools=\"135编辑器\"><section data-width=\"100%\" style=\"width: 677px;text-align: center;\"><section style=\"background-position: center bottom;background-image: url(\" https: repeat-x inline-block><section data-brushtype=\"text\" style=\"padding-right: 12px;padding-bottom: 5px;padding-left: 12px;letter-spacing: 1.5px;font-size: 14px;\">END</section></section></section></section></section></section><p style=\"margin-top: 5px;text-align: center;line-height: 1.75em;letter-spacing: 1.5px;\"><br></p></section></section></section><section data-role=\"paragraph\" style=\"white-space: normal;background-color: rgb(255, 255, 255);font-family: -apple-system-font, BlinkMacSystemFont, \" helvetica neue sc sans gb yahei ui arial sans-serif><section style=\"margin-right: 16px;margin-left: 16px;text-align: center;min-height: 1em;\"><img class=\"rich_pages __bg_gif\" data-cropselx1=\"0\" data-cropselx2=\"546\" data-cropsely1=\"0\" data-cropsely2=\"231\" data-ratio=\"0.42566510172143973\" data-s=\"300,640\" data-type=\"gif\" data-w=\"639\" style=\"box-shadow: rgb(170, 170, 170) 0px 0px 14px 0px; box-sizing: border-box !important; visibility: visible !important; width: 546px !important; max-width: 600px\" src=\"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/LHibUTtMHPRM871k4diaCHnjTxWsaC0HGzZasyqmClIDyvbtm490myxgZ5uRf9RrksOo1rCnC1mLRtvHsAQA6aRw/640?wx_fmt=gif\"></section></section>\n                </div>\n\n    \n        <br>\n        <div id=\"js_toobar3\" class=\"rich_media_tool\">\n            <a target=\"_blank\" href=\"http://www.zhishifenzi.com/\" id=\"js_view_source\" class=\"media_tool_meta meta_primary\">阅读原文</a>\n        </div>\n    \n    <br>\n\n    \n        <a target=\"_blank\" href=\"http://mp.weixin.qq.com/s?__biz=MzIyNDA2NTI4Mg==&amp;mid=2655479550&amp;idx=1&amp;sn=16fe6c16bb1057c19c32fb7774c69c5d&amp;chksm=f3a76493c4d0ed852d851a515c550fb2dc631cc5977ecaafd634a5cdcdedb08c1b69becd2899&amp;scene=0#rd\" style=\"color: blue\" class=\"media_tool_meta meta_primary\">原文</a>\n        <br>\n    \n\n    \n\n    <img alt=\"\" width=\"1px\" height=\"1px\" class=\"\" style=\"width:1px;height:1px;display:none\" src=\"http://www.jintiankansha.me/rss_static/13439/LFA1VWzZ9Z\"></div></div>","descriptionType":"html","publishedDate":"Wed, 11 Aug 2021 00:30:00 +0000","feedId":1531,"bgimg":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRNQmvWZ0NP6gibX1iaRTonfeTx5aHlyKfI1ZbxWcsQUwsiaciaU1trDPz21cUfHmRD0FgrzoAib8BJLa1w/0?wx_fmt=jpeg?imageView2/1/w/600","linkMd5":"14bd9a7ca42db55113376cef35385321","bgimgJsdelivr":"https://cdn.jsdelivr.net/gh/myreaderx21/cdn10@2020_3/2021/08/15/04-30-45-694_9c892e4af6b51097.webp","destWidth":932,"destHeight":396,"sourceBytes":31186,"destBytes":22652,"author":"","articleImgCdnMap":{"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRNQmvWZ0NP6gibX1iaRTonfeTx5aHlyKfI1ZbxWcsQUwsiaciaU1trDPz21cUfHmRD0FgrzoAib8BJLa1w/0?wx_fmt=jpeg?imageView2/1/w/600":"https://cdn.jsdelivr.net/gh/myreaderx21/cdn10@2020_3/2021/08/15/04-30-45-694_9c892e4af6b51097.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRNQmvWZ0NP6gibX1iaRTonfeTZt36TgWq1loShdKp22T5YqeczMKDBrsiapJ9FVpflhTxONsLFVmN1tw/640?wx_fmt=png":"https://cdn.jsdelivr.net/gh/myreaderx6/cdn16@2020_3/2021/08/15/04-31-11-294_40970812442e052d.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/YUyZ7AOL3onWl7HutUicn4iaJ9r2icpgrK2Ut66gZ181iaGWFJaFibibCP2DT4e78Fe2qT8vT1Y5nUpTSupyvVYyiaOYg/640?wx_fmt=png":"https://cdn.jsdelivr.net/gh/myreaderx3/cdn45@2020_2/2021/08/15/04-30-48-327_d3aa2f77dc4e0b53.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1uIDprqnrpyehGEx6GYBP7hiceHlanechCcbvbPyFkany2e2zIyxibRWg/640?wx_fmt=gif":"https://cdn.jsdelivr.net/gh/myreaderx13/cdn35@2020_5/2021/08/15/04-30-47-083_16268415bfeef613.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1u9ib5iawOKyrel83Tog3RBiaJhGJmgxHSsx3mGibpLtdyiahmv407vQuKcw/640?wx_fmt=gif":"https://cdn.jsdelivr.net/gh/myreaderx27/cdn54@2020_3/2021/08/15/04-30-47-103_3f5a5caf8e761bab.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1eSIujfuJjFDyYUbjQUAaNy1icFEHnOV97drE2R6EAxshPtoz8aPLLSg/640?wx_fmt=gif":"https://cdn.jsdelivr.net/gh/myreaderx/cdn73@2020_5/2021/08/15/04-30-46-792_94f73eb0e249abbb.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1IzHStGwKibmYIkGvImBZxibKX0LejQIWFC9cwGx1dicfNoLVbSK7f0LkQ/640?wx_fmt=gif":"https://cdn.jsdelivr.net/gh/myreaderx11/cdn50@2020_2/2021/08/15/04-30-49-514_07058b3f1cb0f858.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1xRUaEePib7nPUBgOaQJfrGIYTA77ZsGpbEyd7PbYNpAkM5IVQf0t5mg/640?wx_fmt=gif":"https://cdn.jsdelivr.net/gh/myreaderx5oss/cdn25@2020_1/2021/08/15/04-30-49-709_f2fdf1b181c17ca2.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1ricSyknndpMBaK5Tjk2vcx0of3l4oKCyWFyEF0Yq5t974WPFicRCYSXw/640?wx_fmt=gif":"https://cdn.jsdelivr.net/gh/myreaderx33/cdn18@2020_4/2021/08/15/04-30-47-736_bd2651a4a8696ab7.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRM5Ud8d7rOrOJZmevzXI7jkWPQBKNS1T4U2CFbBsLHLZqKukUV52RiaDRiaVKuLnOshZeeEDWuDse3w/640?wx_fmt=png":"https://cdn.jsdelivr.net/gh/myreaderx18/cdn72@2020_3/2021/08/15/04-30-46-689_8ae0aba223f05c44.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRO3Sj5JqOfIxBuplfCx6EdiaHeBopib80SfvU0pKAvPD1rjefmLAcX9sIJGkqgTxK0GsNWjlufSuzKg/640?wx_fmt=jpeg":null,"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/LHibUTtMHPRM5Ud8d7rOrOJZmevzXI7jkbtS6NgcCtYfhOYnbRDqWPyibaelA4pIB0lvdg99hJfsmdibm2Eibg6dDQ/640?wx_fmt=gif":"https://cdn.jsdelivr.net/gh/myreaderx8/cdn59@2020_6/2021/08/15/04-30-46-765_5172cd85a08ee73b.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/lBLXrFcccXFwZwrMI7x3Idm0WicwB4ibviaNqA7dU3PEVQZrafvvMVQV4muo1DuHlPLtLIAwFbMWic5VGyn7G1vIuQ/640?wx_fmt=gif":"https://cdn.jsdelivr.net/gh/myreaderx19/cdn58@2020_4/2021/08/15/04-30-47-495_bf9d412e67e73107.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRNQmvWZ0NP6gibX1iaRTonfeT0elRibzgOSXQjFbVlxwdIaibHBkFMATRmXn52h3jHo1PWf2IcVu7UOAQ/640?wx_fmt=jpeg":"https://cdn.jsdelivr.net/gh/myreaderx7/cdn66@2020_1/2021/08/15/04-30-46-959_dfd772a4014b7e42.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRMe9wA4tOj4PflDJ7GITMsXqzKllK1PTSglkLTkVVZHsHlVkPReUw9eCqdXHjDOQOArP0xDZibn3Xg/640?wx_fmt=jpeg":"https://cdn.jsdelivr.net/gh/myreaderx32/cdn28@2020_5/2021/08/15/04-30-49-934_3029711b40aa3218.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRP0zxsk2TMjOnBEVlg7iciaJY93KSTmibPiaQMWK0mRuiagdEpUuI2NASRiciaJSmI7xOsYcNU2CQtDL6B8A/640?wx_fmt=jpeg":"https://cdn.jsdelivr.net/gh/myreaderx24/cdn13@2020_5/2021/08/15/04-30-47-014_74430bc968b4cc7d.webp","http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/LHibUTtMHPRM871k4diaCHnjTxWsaC0HGzZasyqmClIDyvbtm490myxgZ5uRf9RrksOo1rCnC1mLRtvHsAQA6aRw/640?wx_fmt=gif":"https://cdn.jsdelivr.net/gh/myreaderx25/cdn41@2020_5/2021/08/15/04-30-48-584_53230ba3aabf500c.webp","http://www.jintiankansha.me/rss_static/13439/LFA1VWzZ9Z":null},"publishedOrCreatedDate":1629001842422}],"record":{"createdTime":"2021-08-15 12:30:42","updatedTime":"2021-08-15 12:30:42","feedId":1531,"fetchDate":"Sun, 15 Aug 2021 04:30:42 +0000","fetchMs":656,"handleMs":18,"totalMs":30295,"newArticles":0,"totalArticles":5,"status":1,"type":0,"ip":"af6ca12eefe249e94a3f077d15d7c168","hostName":"europe64*","requestId":"5865e01d4b2d4354b6080e07b1661e20_1531","contentType":"application/rss+xml","totalBytes":458630,"bgimgsTotal":1,"bgimgsGithubTotal":1,"articlesImgsTotal":18,"articlesImgsGithubTotal":16,"successGithubMap":{"myreaderx8":1,"myreaderx25":1,"myreaderx7":1,"myreaderx27":1,"myreaderx6":1,"myreaderx21":1,"myreaderx32":1,"myreaderx11":1,"myreaderx3":1,"myreaderx33":1,"myreaderx24":1,"myreaderx13":1,"myreaderx5oss":1,"myreaderx18":1,"myreaderx19":1,"myreaderx":1},"failGithubMap":{"myreaderx31":1}},"feed":{"createdTime":"2020-08-24 21:31:30","updatedTime":"2020-09-01 09:48:48","id":1531,"name":"知识分子","url":"http://feedmaker.kindle4rss.com/feeds/The-Intellectual.weixin.xml","subscriber":null,"website":null,"icon":"http://www.sogou.com/images/logo/new/favicon.ico?v=4","icon_jsdelivr":"https://cdn.jsdelivr.net/gh/myreaderx65/cdn45@2020_1/2020/09/01/01-48-33-569_d24121c9beed1de6.ico","description":"《知识分子》是由饶毅、鲁白、谢宇三位学者创办的移动新媒体平台，致力于关注科学、人文、思想。我们将兼容并包，时刻为渴望知识、独立思考的人努力，共享人类知识、共析现代思想、共建智趣中国。欢迎关注。","weekly":null,"link":null},"noPictureArticleList":[{"createdTime":"2021-08-15 12:31:11","updatedTime":"2021-08-15 12:31:11","id":null,"feedId":1531,"linkMd5":"14bd9a7ca42db55113376cef35385321"}],"tmpCommonImgCdnBytes":22652,"tmpBodyImgCdnBytes":435978,"tmpBgImgCdnBytes":0,"extra4":{"start":1629001841322,"total":0,"statList":[{"spend":1082,"msg":"获取xml内容"},{"spend":18,"msg":"解释文章"},{"spend":0,"msg":"上传封面图到cdn"},{"spend":0,"msg":"修正封面图上传失败重新上传"},{"spend":25476,"msg":"正文链接上传到cdn"}]},"extra5":18,"extra6":18,"extra7ImgCdnFailResultVector":[{"code":1,"isDone":false,"source":"http://www.jintiankansha.me/rss_static/13439/LFA1VWzZ9Z","sourceStatusCode":405,"sourceBytes":0,"destBytes":0,"feedId":1531,"totalSpendMs":764,"convertSpendMs":0,"createdTime":"2021-08-15 12:30:46","host":"europe-59*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[405],"sourceSize":"0","destSize":"0"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRO3Sj5JqOfIxBuplfCx6EdiaHeBopib80SfvU0pKAvPD1rjefmLAcX9sIJGkqgTxK0GsNWjlufSuzKg/640?wx_fmt=jpeg","sourceStatusCode":200,"destWidth":760,"destHeight":322,"sourceBytes":17278,"destBytes":14732,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":859,"convertSpendMs":7,"createdTime":"2021-08-15 12:30:46","host":"us-52*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","rawMap":{"githubUrl":"https://api.github.com/repos/myreaderx31/cdn33/contents/2021/08/15/04-30-47-039_f64a697ea83b873c.webp","resp":{"code":403,"msg":"Forbidden","body":"{\n  \"message\": \"API rate limit exceeded for user ID 69855631.\",\n  \"documentation_url\": \"https://docs.github.com/rest/overview/resources-in-the-rest-api#rate-limiting\"\n}\n","headerMap":{"access-control-allow-origin":["*"],"access-control-expose-headers":["ETag, Link, Location, Retry-After, X-GitHub-OTP, X-RateLimit-Limit, X-RateLimit-Remaining, X-RateLimit-Used, X-RateLimit-Resource, X-RateLimit-Reset, X-OAuth-Scopes, X-Accepted-OAuth-Scopes, X-Poll-Interval, X-GitHub-Media-Type, Deprecation, Sunset"],"content-security-policy":["default-src 'none'"],"content-type":["application/json; charset=utf-8"],"date":["Sun, 15 Aug 2021 04:30:47 GMT"],"referrer-policy":["origin-when-cross-origin, strict-origin-when-cross-origin"],"server":["GitHub.com"],"strict-transport-security":["max-age=31536000; includeSubdomains; preload"],"transfer-encoding":["chunked"],"vary":["Accept-Encoding, Accept, X-Requested-With"],"x-accepted-oauth-scopes":["repo"],"x-content-type-options":["nosniff"],"x-frame-options":["deny"],"x-github-media-type":["github.v3; format=json"],"x-github-request-id":["B458:5505:9C169F:125A891:61189877"],"x-oauth-scopes":["admin:enterprise, admin:gpg_key, admin:org, admin:org_hook, admin:public_key, admin:repo_hook, delete:packages, delete_repo, gist, notifications, repo, user, workflow, write:discussion, write:packages"],"x-ratelimit-limit":["60"],"x-ratelimit-remaining":["0"],"x-ratelimit-reset":["1629003203"],"x-ratelimit-resource":["core"],"x-ratelimit-used":["60"],"x-xss-protection":["0"]},"exceptionMsg":"Unexpected code 403,url is : https://api.github.com/repos/myreaderx31/cdn33/contents/2021/08/15/04-30-47-039_f64a697ea83b873c.webp","historyStatusCode":[],"spendMs":84},"base64UserPassword":null,"token":"da243******************************d9e47"},"githubUser":"myreaderx31","githubHttpCode":403,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"16.9 KB","destSize":"14.4 KB","compressRate":"85.3%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1xRUaEePib7nPUBgOaQJfrGIYTA77ZsGpbEyd7PbYNpAkM5IVQf0t5mg/640?wx_fmt=gif","sourceStatusCode":403,"sourceBytes":0,"destBytes":0,"feedId":1531,"totalSpendMs":1128,"convertSpendMs":0,"createdTime":"2021-08-15 12:30:46","host":"us-002*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","extra22GetBytesInfo":"2、Referer字段 ： http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","extra23historyStatusCode":[403,403],"sourceSize":"0","destSize":"0"},{"code":1,"isDone":false,"source":"http://www.jintiankansha.me/rss_static/13439/LFA1VWzZ9Z","sourceStatusCode":405,"sourceBytes":0,"destBytes":0,"feedId":1531,"totalSpendMs":680,"convertSpendMs":0,"createdTime":"2021-08-15 12:30:47","host":"us-006*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[405],"sourceSize":"0","destSize":"0"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRO3Sj5JqOfIxBuplfCx6EdiaHeBopib80SfvU0pKAvPD1rjefmLAcX9sIJGkqgTxK0GsNWjlufSuzKg/640?wx_fmt=jpeg","sourceStatusCode":200,"destWidth":760,"destHeight":322,"sourceBytes":17278,"destBytes":14732,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":2871,"convertSpendMs":9,"createdTime":"2021-08-15 12:30:47","host":"us-035*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","rawMap":{"githubUrl":"https://api.github.com/repos/myreaderx31/cdn33/contents/2021/08/15/04-30-50-043_f64a697ea83b873c.webp","resp":{"code":403,"msg":"Forbidden","body":"{\n  \"message\": \"API rate limit exceeded for user ID 69855631.\",\n  \"documentation_url\": \"https://docs.github.com/rest/overview/resources-in-the-rest-api#rate-limiting\"\n}\n","headerMap":{"access-control-allow-origin":["*"],"access-control-expose-headers":["ETag, Link, Location, Retry-After, X-GitHub-OTP, X-RateLimit-Limit, X-RateLimit-Remaining, X-RateLimit-Used, X-RateLimit-Resource, X-RateLimit-Reset, X-OAuth-Scopes, X-Accepted-OAuth-Scopes, X-Poll-Interval, X-GitHub-Media-Type, Deprecation, Sunset"],"content-security-policy":["default-src 'none'"],"content-type":["application/json; charset=utf-8"],"date":["Sun, 15 Aug 2021 04:30:50 GMT"],"referrer-policy":["origin-when-cross-origin, strict-origin-when-cross-origin"],"server":["GitHub.com"],"strict-transport-security":["max-age=31536000; includeSubdomains; preload"],"transfer-encoding":["chunked"],"vary":["Accept-Encoding, Accept, X-Requested-With"],"x-accepted-oauth-scopes":["repo"],"x-content-type-options":["nosniff"],"x-frame-options":["deny"],"x-github-media-type":["github.v3; format=json"],"x-github-request-id":["80FC:0EE9:4E34E7:B91E98:6118987A"],"x-oauth-scopes":["admin:enterprise, admin:gpg_key, admin:org, admin:org_hook, admin:public_key, admin:repo_hook, delete:packages, delete_repo, gist, notifications, repo, user, workflow, write:discussion, write:packages"],"x-ratelimit-limit":["60"],"x-ratelimit-remaining":["0"],"x-ratelimit-reset":["1629003203"],"x-ratelimit-resource":["core"],"x-ratelimit-used":["60"],"x-xss-protection":["0"]},"exceptionMsg":"Unexpected code 403,url is : https://api.github.com/repos/myreaderx31/cdn33/contents/2021/08/15/04-30-50-043_f64a697ea83b873c.webp","historyStatusCode":[],"spendMs":29},"base64UserPassword":null,"token":"da243******************************d9e47"},"githubUser":"myreaderx31","githubHttpCode":403,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"16.9 KB","destSize":"14.4 KB","compressRate":"85.3%"}],"extra10_invalidATagHrefValue":{},"extra111_proxyServerAndStatMap":{"http://us-53.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-002.herokuapp.com/":{"failCount":1,"successCount":0,"resultList":[403]},"http://us-007.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-034.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-035.herokuapp.com/":{"failCount":0,"successCount":2,"resultList":[200,200]},"http://europe61.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://europe-60.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-52.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://europe70.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-026.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-006.herokuapp.com/":{"failCount":1,"successCount":0,"resultList":[405]},"http://us-025.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-031.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-019.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-010.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://europe-59.herokuapp.com/":{"failCount":1,"successCount":0,"resultList":[405]},"http://us-003.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-023.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]},"http://us-027.herokuapp.com/":{"failCount":0,"successCount":1,"resultList":[200]}},"extra12ImgCdnSuccessResultVector":[{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRNQmvWZ0NP6gibX1iaRTonfeTx5aHlyKfI1ZbxWcsQUwsiaciaU1trDPz21cUfHmRD0FgrzoAib8BJLa1w/0?wx_fmt=jpeg?imageView2/1/w/600","sourceStatusCode":200,"destWidth":932,"destHeight":396,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx21/cdn10@2020_3/2021/08/15/04-30-45-694_9c892e4af6b51097.webp","sourceBytes":31186,"destBytes":22652,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":3692,"convertSpendMs":11,"createdTime":"2021-08-15 12:30:42","host":"europe-24*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321,14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx21","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"30.5 KB","destSize":"22.1 KB","compressRate":"72.6%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/LHibUTtMHPRM5Ud8d7rOrOJZmevzXI7jkbtS6NgcCtYfhOYnbRDqWPyibaelA4pIB0lvdg99hJfsmdibm2Eibg6dDQ/640?wx_fmt=gif","sourceStatusCode":200,"destWidth":200,"destHeight":200,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx8/cdn59@2020_6/2021/08/15/04-30-46-765_5172cd85a08ee73b.webp","sourceBytes":14253,"destBytes":22552,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":752,"convertSpendMs":26,"createdTime":"2021-08-15 12:30:46","host":"us-035*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx8","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"13.9 KB","destSize":"22 KB","compressRate":"158.2%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRM5Ud8d7rOrOJZmevzXI7jkWPQBKNS1T4U2CFbBsLHLZqKukUV52RiaDRiaVKuLnOshZeeEDWuDse3w/640?wx_fmt=png","sourceStatusCode":200,"destWidth":92,"destHeight":90,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx18/cdn72@2020_3/2021/08/15/04-30-46-689_8ae0aba223f05c44.webp","sourceBytes":4625,"destBytes":2870,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":912,"convertSpendMs":10,"createdTime":"2021-08-15 12:30:46","host":"europe-60*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx18","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"4.5 KB","destSize":"2.8 KB","compressRate":"62.1%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRNQmvWZ0NP6gibX1iaRTonfeT0elRibzgOSXQjFbVlxwdIaibHBkFMATRmXn52h3jHo1PWf2IcVu7UOAQ/640?wx_fmt=jpeg","sourceStatusCode":200,"destWidth":960,"destHeight":242,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx7/cdn66@2020_1/2021/08/15/04-30-46-959_dfd772a4014b7e42.webp","sourceBytes":26936,"destBytes":25532,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":960,"convertSpendMs":9,"createdTime":"2021-08-15 12:30:46","host":"us-010*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx7","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"26.3 KB","destSize":"24.9 KB","compressRate":"94.8%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1eSIujfuJjFDyYUbjQUAaNy1icFEHnOV97drE2R6EAxshPtoz8aPLLSg/640?wx_fmt=gif","sourceStatusCode":200,"destWidth":400,"destHeight":400,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx/cdn73@2020_5/2021/08/15/04-30-46-792_94f73eb0e249abbb.webp","sourceBytes":10601,"destBytes":33412,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":1136,"convertSpendMs":110,"createdTime":"2021-08-15 12:30:46","host":"europe61*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"10.4 KB","destSize":"32.6 KB","compressRate":"315.2%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRP0zxsk2TMjOnBEVlg7iciaJY93KSTmibPiaQMWK0mRuiagdEpUuI2NASRiciaJSmI7xOsYcNU2CQtDL6B8A/640?wx_fmt=jpeg","sourceStatusCode":200,"destWidth":960,"destHeight":242,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx24/cdn13@2020_5/2021/08/15/04-30-47-014_74430bc968b4cc7d.webp","sourceBytes":23858,"destBytes":18778,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":1016,"convertSpendMs":9,"createdTime":"2021-08-15 12:30:46","host":"us-027*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx24","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"23.3 KB","destSize":"18.3 KB","compressRate":"78.7%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1uIDprqnrpyehGEx6GYBP7hiceHlanechCcbvbPyFkany2e2zIyxibRWg/640?wx_fmt=gif","sourceStatusCode":200,"destWidth":400,"destHeight":400,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx13/cdn35@2020_5/2021/08/15/04-30-47-083_16268415bfeef613.webp","sourceBytes":10094,"destBytes":29578,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":1054,"convertSpendMs":119,"createdTime":"2021-08-15 12:30:46","host":"us-53*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx13","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"9.9 KB","destSize":"28.9 KB","compressRate":"293%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1u9ib5iawOKyrel83Tog3RBiaJhGJmgxHSsx3mGibpLtdyiahmv407vQuKcw/640?wx_fmt=gif","sourceStatusCode":200,"destWidth":400,"destHeight":400,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx27/cdn54@2020_3/2021/08/15/04-30-47-103_3f5a5caf8e761bab.webp","sourceBytes":10419,"destBytes":32796,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":1533,"convertSpendMs":114,"createdTime":"2021-08-15 12:30:46","host":"europe70*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx27","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"10.2 KB","destSize":"32 KB","compressRate":"314.8%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/lBLXrFcccXFwZwrMI7x3Idm0WicwB4ibviaNqA7dU3PEVQZrafvvMVQV4muo1DuHlPLtLIAwFbMWic5VGyn7G1vIuQ/640?wx_fmt=gif","sourceStatusCode":200,"destWidth":462,"destHeight":40,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx19/cdn58@2020_4/2021/08/15/04-30-47-495_bf9d412e67e73107.webp","sourceBytes":68255,"destBytes":82152,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":1484,"convertSpendMs":118,"createdTime":"2021-08-15 12:30:46","host":"us-034*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx19","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"66.7 KB","destSize":"80.2 KB","compressRate":"120.4%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1ricSyknndpMBaK5Tjk2vcx0of3l4oKCyWFyEF0Yq5t974WPFicRCYSXw/640?wx_fmt=gif","sourceStatusCode":200,"destWidth":400,"destHeight":400,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx33/cdn18@2020_4/2021/08/15/04-30-47-736_bd2651a4a8696ab7.webp","sourceBytes":10875,"destBytes":36076,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":1761,"convertSpendMs":114,"createdTime":"2021-08-15 12:30:46","host":"us-026*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx33","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"10.6 KB","destSize":"35.2 KB","compressRate":"331.7%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/YUyZ7AOL3onWl7HutUicn4iaJ9r2icpgrK2Ut66gZ181iaGWFJaFibibCP2DT4e78Fe2qT8vT1Y5nUpTSupyvVYyiaOYg/640?wx_fmt=png","sourceStatusCode":200,"destWidth":66,"destHeight":66,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx3/cdn45@2020_2/2021/08/15/04-30-48-327_d3aa2f77dc4e0b53.webp","sourceBytes":4014,"destBytes":2366,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":2275,"convertSpendMs":4,"createdTime":"2021-08-15 12:30:46","host":"us-019*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx3","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"3.9 KB","destSize":"2.3 KB","compressRate":"58.9%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/LHibUTtMHPRM871k4diaCHnjTxWsaC0HGzZasyqmClIDyvbtm490myxgZ5uRf9RrksOo1rCnC1mLRtvHsAQA6aRw/640?wx_fmt=gif","sourceStatusCode":200,"destWidth":639,"destHeight":272,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx25/cdn41@2020_5/2021/08/15/04-30-48-584_53230ba3aabf500c.webp","sourceBytes":26623,"destBytes":12888,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":2538,"convertSpendMs":66,"createdTime":"2021-08-15 12:30:46","host":"us-031*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx25","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"26 KB","destSize":"12.6 KB","compressRate":"48.4%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1IzHStGwKibmYIkGvImBZxibKX0LejQIWFC9cwGx1dicfNoLVbSK7f0LkQ/640?wx_fmt=gif","sourceStatusCode":200,"destWidth":400,"destHeight":400,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx11/cdn50@2020_2/2021/08/15/04-30-49-514_07058b3f1cb0f858.webp","sourceBytes":10645,"destBytes":33614,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":3478,"convertSpendMs":123,"createdTime":"2021-08-15 12:30:46","host":"us-007*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx11","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"10.4 KB","destSize":"32.8 KB","compressRate":"315.8%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_gif/7QRTvkK2qC6D2OhibHUMz1XiaC7v0RcUA1xRUaEePib7nPUBgOaQJfrGIYTA77ZsGpbEyd7PbYNpAkM5IVQf0t5mg/640?wx_fmt=gif","sourceStatusCode":200,"destWidth":400,"destHeight":400,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx5oss/cdn25@2020_1/2021/08/15/04-30-49-709_f2fdf1b181c17ca2.webp","sourceBytes":10507,"destBytes":32334,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":2386,"convertSpendMs":101,"createdTime":"2021-08-15 12:30:47","host":"us-023*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx5oss","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"10.3 KB","destSize":"31.6 KB","compressRate":"307.7%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_jpg/LHibUTtMHPRMe9wA4tOj4PflDJ7GITMsXqzKllK1PTSglkLTkVVZHsHlVkPReUw9eCqdXHjDOQOArP0xDZibn3Xg/640?wx_fmt=jpeg","sourceStatusCode":200,"destWidth":960,"destHeight":242,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx32/cdn28@2020_5/2021/08/15/04-30-49-934_3029711b40aa3218.webp","sourceBytes":41865,"destBytes":36174,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":3912,"convertSpendMs":15,"createdTime":"2021-08-15 12:30:46","host":"us-003*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx32","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"40.9 KB","destSize":"35.3 KB","compressRate":"86.4%"},{"code":1,"isDone":false,"source":"http://img2.jintiankansha.me/get?src=http://mmbiz.qpic.cn/mmbiz_png/LHibUTtMHPRNQmvWZ0NP6gibX1iaRTonfeTZt36TgWq1loShdKp22T5YqeczMKDBrsiapJ9FVpflhTxONsLFVmN1tw/640?wx_fmt=png","sourceStatusCode":200,"destWidth":932,"destHeight":720,"fixedGithubDest":"https://cdn.jsdelivr.net/gh/myreaderx6/cdn16@2020_3/2021/08/15/04-31-11-294_40970812442e052d.webp","sourceBytes":235202,"destBytes":34856,"targetWebpQuality":75,"feedId":1531,"totalSpendMs":25307,"convertSpendMs":30,"createdTime":"2021-08-15 12:30:46","host":"us-025*","referer":"http://weixin.sogou.com/weixin?type=2&query=%E7%9F%A5%E8%AF%86%E5%88%86%E5%AD%90+%E5%BE%B7%E5%B0%94%E5%A1%94%E9%98%B4%E5%BD%B1%E4%B8%8B%EF%BC%8CmRNA%E7%96%AB%E8%8B%97%E8%83%BD%E6%88%90%E4%B8%BA%E7%96%AB%E6%83%85%E8%A7%A3%E8%8D%AF%E5%90%97%EF%BC%9F","linkMd5ListStr":"14bd9a7ca42db55113376cef35385321","githubUser":"myreaderx6","githubHttpCode":201,"extra22GetBytesInfo":"1、没有Referer字段","extra23historyStatusCode":[200],"sourceSize":"229.7 KB","destSize":"34 KB","compressRate":"14.8%"}],"successGithubMap":{"myreaderx8":1,"myreaderx25":1,"myreaderx7":1,"myreaderx27":1,"myreaderx6":1,"myreaderx21":1,"myreaderx32":1,"myreaderx11":1,"myreaderx3":1,"myreaderx33":1,"myreaderx24":1,"myreaderx13":1,"myreaderx5oss":1,"myreaderx18":1,"myreaderx19":1,"myreaderx":1},"failGithubMap":{"myreaderx31":1}}